AstraZeneca maintains European product monopoly for Arimidex (Anastrozole) with the grant of a Paediatric extension

Sydney, Australia, September 2010: GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article based on its proprietary patent intelligence for Arimidex® (Anastrozole), AstraZeneca’s blockbuster drug for the treatment of breast cancer. The article analyses the surrounding patent landscape, highlighting the need for comprehensive, up-to-date information in the development of launch strategies that minimise the cost of litigation and understanding the barriers to launch as to receive the benefits of your generic product being first to market.

Key findings of the article include:

# The term of the European equivalent patent protecting the active ingredient for Arimidex®

Related posts:

1. OKI Cuts CO2 Emissions by 17% at Its European Manufacturing Facility
2. AhnLab to Protect European Online Banking Market from ZeuS Trojan with ‘AhnLab Online Security’
3. FFS Pellet Mills Welcomes Potential Investment From The European Research Commission